ORTHOCELL LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.39 AUD | +4.00% |
|
0.00% | -4.88% |
| 15/04 | Orthocell Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 3% | MT |
| 09/04 | Orthocell Revenue Soars 19% to AU$1.61 Million in Q1 | MT |
| Sales 2022 | 1.53M 1.01M 83.8M | Sales 2023 | 4.24M 2.78M 232M | Capitalization | 69.06M 45.32M 3.78B |
|---|---|---|---|---|---|
| Net income 2022 | -9M -5.91M -492M | Net income 2023 | -6M -3.94M -328M | EV / Sales 2022 | 45.3 x |
| Net cash position 2022 | 10.51M 6.9M 575M | Net cash position 2023 | 24.26M 15.92M 1.33B | EV / Sales 2023 | 10.6 x |
| P/E ratio 2022 |
-8.62
x | P/E ratio 2023 |
-10.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 74.71% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +4.00% | ||
| 1 month | +1.30% | ||
| 3 months | +2.63% | ||
| 6 months | +18.18% | ||
| Current year | -4.88% |
1 week
0.38
0.39
1 month
0.370.42
Current year
0.370.45
1 year
0.320.46
3 years
0.300.66
5 years
0.110.78
10 years
0.110.99
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Hao Zheng
FOU | Founder | - | 21/06/21 |
Paul Anderson
FOU | Founder | 58 | 21/06/21 |
Nicole Telford
DFI | Director of Finance/CFO | - | 01/06/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 25/23/25 | |
| Chairman | - | 01/23/01 | |
Ravi Thadhani
BRD | Director/Board Member | - | 08/23/08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 0.39 | +4.00% | 8 000 |
| 26/24/26 | 0.375 | -1.32% | 33,180 |
| 24/24/24 | 0.38 | +1.33% | 89,516 |
| 23/24/23 | 0.375 | -3.85% | 297,614 |
| 22/24/22 | 0.39 | -1.27% | 184,319 |
Delayed Quote Australian S.E., April 29, 2024 at 08:55 am IST
More quotes
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes CelGro, Striate+, Remplir, and SmrtGraft. CelGro is a collagen medical device that facilitates tissue reconstruction and healing in a variety of dental and orthopedic reconstructive applications. CelGro is manufactured using a SMRT manufacturing process to preserve the natural collagen structure. Striate+ is used for dental GBR applications. Remplir is for peripheral nerve reconstruction. SmrtGraft is for tendon repair. Its other major products are autologous cell therapy, which focuses on regenerating damaged tendon and cartilage tissue. It is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Calendar
29/08/2024
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.88% | 51.19M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- OCC Stock
